22nd Century is a plant biotechnology company focused on technology which allows it to decrease the level of nicotine in tobacco plants and modify the levels of cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The Company's primary mission in tobacco is to reduce the harm caused by smoking. The Company's primary mission in hemp/cannabis is to develop proprietary hemp strains for important new medicines and agricultural crops.

Company profile
Ticker
XXII
Exchange
Website
CEO
James A Mish
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Philip Morris International • Altria • Vector • RLX Technology • TILT • Hempacco • BOTS • Reynolds American • A1 • RJ Reynolds Tobacco ...
Former names
Touchstone Mining LTD
SEC CIK
Corporate docs
Subsidiaries
22nd Century Limited, LLC • Goodrich Tobacco Company, LLC • Heracles Pharmaceuticals, LLC • NASCO Products, LLC • Botanical Genetics, LLC • 22nd Century Group Europe B.V. • 22nd Century Group Canada, Inc. • 22nd Century Holdings, LLC • Golden Acquisition Sub, LLC • ESI Holdings, LLC ...
IRS number
980468420
XXII stock data
Latest filings (excl ownership)
10-K/A
2022 FY
Annual report (amended)
28 Mar 23
8-K
Entry into a Material Definitive Agreement
10 Mar 23
S-3
Shelf registration
10 Mar 23
8-K/A
Unaudited Pro Forma Condensed Combined Financial Statements
10 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Results of Operations and Financial Condition
9 Mar 23
8-K
22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives
3 Mar 23
8-K
22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
24 Jan 23
8-K
22nd Century Group Provides Update on Incident at Grass Valley Facility
21 Nov 22
8-K
Departure of Directors or Certain Officers
17 Nov 22
Transcripts
XXII
Earnings call transcript
2022 Q4
9 Mar 23
XXII
Earnings call transcript
2022 Q3
9 Nov 22
XXII
Earnings call transcript
2022 Q2
9 Aug 22
XXII
Earnings call transcript
2022 Q1
5 May 22
XXII
Earnings call transcript
2021 Q4
1 Mar 22
XXII
Earnings call transcript
2021 Q3
4 Nov 21
XXII
Earnings call transcript
2021 Q2
5 Aug 21
XXII
Earnings call transcript
2021 Q1
6 May 21
XXII
Earnings call transcript
2020 Q4
11 Mar 21
XXII
Earnings call transcript
2020 Q3
5 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.05 mm | 5.02 mm | 6.36 mm | 4.31 mm |
Cash used (since last report) | n/a | n/a | 23.98 mm | 14.96 mm | 18.94 mm | 12.85 mm |
Cash remaining | n/a | n/a | -20.96 mm | -11.94 mm | -15.92 mm | -9.83 mm |
Runway (months of cash) | n/a | n/a | -2.6 | -2.4 | -2.5 | -2.3 |
Institutional ownership, Q4 2022
19.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 131 |
Opened positions | 15 |
Closed positions | 18 |
Increased positions | 42 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 38.19 bn |
Total shares | 42.30 mm |
Total puts | 251.90 k |
Total calls | 282.70 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 10.75 mm | $9.89 bn |
Vanguard | 10.36 mm | $9.53 bn |
Geode Capital Management | 3.45 mm | $3.21 bn |
STT State Street | 2.92 mm | $2.69 bn |
Etf Managers | 2.54 mm | $2.34 bn |
NTRS Northern Trust | 1.44 mm | $1.33 bn |
HighTower Advisors | 1.20 mm | $1.10 bn |
Mirae Asset Global Investments | 1.15 mm | $1.06 bn |
BK Bank Of New York Mellon | 563.54 k | $518.74 mm |
Vident Investment Advisory | 506.21 k | $465.71 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 23 | John Franzino | Common Stock | Payment of exercise | Dispose F | No | No | 0.8724 | 14,244 | 12.43 k | 605,949 |
21 Mar 23 | James A Mish | Common Stock | Payment of exercise | Dispose F | No | No | 0.8724 | 225,841 | 197.02 k | 2,137,954 |
19 Mar 23 | John Franzino | Common Stock | Payment of exercise | Dispose F | No | No | 0.8719 | 21,210 | 18.49 k | 620,193 |
19 Mar 23 | James A Mish | Common Stock | Payment of exercise | Dispose F | No | No | 0.8719 | 54,735 | 47.72 k | 2,363,795 |
14 Mar 23 | Michael Koganov | Common Stock | Grant | Acquire A | No | No | 0 | 128,342 | 0.00 | 307,714 |
14 Mar 23 | John Franzino | Common Stock | Grant | Acquire A | No | No | 0 | 235,829 | 0.00 | 641,403 |
14 Mar 23 | Lucille S Salhany | Common Stock | Grant | Acquire A | No | No | 0 | 128,342 | 0.00 | 155,954 |
News
Bearish Sentiment Across The Cannabis Space - Check Full Movers For March 24, 2023
24 Mar 23
Bearish Sentiment Across The Cannabis Space - Check Full Movers For March 23, 2023
23 Mar 23
Stocks That Hit 52-Week Lows On Thursday
23 Mar 23
Cannabis Stock Movers For March 22, 2023
22 Mar 23
Bullish Tuesday For Marijuana Stocks - Aurora Cannabis, OrganiGram Holdings Among Top Gainers
21 Mar 23
Press releases
22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
9 Mar 23
22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives
3 Mar 23
22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference
2 Mar 23
22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
24 Jan 23
22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
23 Jan 23